Profile

Our research focuses on the control of blood cell production and how this is subverted in hematologic malignancy. We have been particularly interested in the oncogene TAL1 (or SCL) that encodes a member of the helix-loop-helix family of transcription factors. Abnormal expression of this gene, originally identified through its involvement by a recurrent chromosomal translocation, constitutes the most frequent gain-of-function mutation in T-cell acute lymphoblastic leukemia (T-ALL). Many helix-loop-helix proteins are important in specification of cell fate, and studies from our lab and others indicate that TAL1 regulates fundamental aspects of hematopoietic differentiation.

We have characterized in detail the expression of TAL1 protein in murine and avian embryogenesis and, most recently, in physiological and pathological vasculogenesis. A series of studies on TAL1 function in erythroid cells have shown this transcription factor undergoes both phosphorylation and acetylation, and we have investigated its interaction with a number of transcriptional coregulators. Work is ongoing to investigate the mechanism by which misexpression of this critical regulator of normal hematopoiesis contributes to leukemic transformation and to identify both its interaction partners and downstream targets. Contemporary techniques of molecular biology and protein biochemistry and both in vitro and in vivo models are used in this research.

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Requirement for ssbp2 in hematopoietic stem cell maintenance and stress response. Li J, Kurasawa Y, Wang Y, Clise-Dwyer K, Klumpp SA, Liang H, Tailor RC, Raymond AC, Estrov Z, Brandt SJ, Davis RE, Zweidler-McKay P, Amin HM, Nagarajan L (2014) J Immunol 193(9): 4654-62
    › Primary publication · 25238756 (PubMed) · PMC4201964 (PubMed Central)
  2. Immunomodulatory nonablative conditioning regimen for B-cell lymphoid malignancies. Chinratanalab W, Reddy N, Greer JP, Morgan D, Engelhardt B, Kassim A, Brandt SJ, Jagasia M, Goodman S, Savani BN (2012) Exp Hematol 40(6): 431-5
    › Primary publication · 22269114 (PubMed) · PMC4067702 (PubMed Central)
  3. SSBP2 is an in vivo tumor suppressor and regulator of LDB1 stability. Wang Y, Klumpp S, Amin HM, Liang H, Li J, Estrov Z, Zweidler-McKay P, Brandt SJ, Agulnick A, Nagarajan L (2010) Oncogene 29(21): 3044-53
    › Primary publication · 20348955 (PubMed) · PMC2878399 (PubMed Central)
  4. Regulation of LMO2 mRNA and protein expression in erythroid differentiation. Brandt SJ, Koury MJ (2009) Haematologica 94(4): 447-8
    › Primary publication · 19336746 (PubMed) · PMC2663604 (PubMed Central)
  5. Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia. Odenike OM, Alkan S, Sher D, Godwin JE, Huo D, Brandt SJ, Green M, Xie J, Zhang Y, Vesole DH, Stiff P, Wright J, Larson RA, Stock W (2008) Clin Cancer Res 14(21): 7095-101
    › Primary publication · 18981008 (PubMed) · PMC4498482 (PubMed Central)
  6. BRCA1 accumulates in the nucleus in response to hypoxia and TRAIL and enhances TRAIL-induced apoptosis in breast cancer cells. Fitzgerald LD, Bailey CK, Brandt SJ, Thompson ME (2007) FEBS J 274(19): 5137-46
    › Primary publication · 17803681 (PubMed)
  7. Spliced isoforms of LIM-domain-binding protein (CLIM/NLI/Ldb) lacking the LIM-interaction domain. Tran YH, Xu Z, Kato A, Mistry AC, Goya Y, Taira M, Brandt SJ, Hirose S (2006) J Biochem 140(1): 105-19
    › Primary publication · 16815859 (PubMed)